Publication

Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development

A new paper argues context of use, not NAMs-versus-animals, should govern nonclinical strategy in drug…

Danielle PillsburySeptember 9, 2026

Live Events

Tailwinds for MIDD: EMA, FDA, and a Converging Regulatory Landscape

October 29, 2026 - 11:00 PM – 2:00 PM

CertaraSeptember 9, 2026

Publication

A glimpse into the future of model-informed drug discovery and development

Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…

CertaraAugust 28, 2026

Webinar

The Road to First-in-Human: Model-Informed Decisions from Discovery to First Dose

Danielle PillsburyAugust 28, 2026

Live Events

Tailwinds for MIDD: What to Know About the Changing Regulatory Landscape

September 30, 2026 - 11:30 PM – 2:00 PM

CertaraAugust 12, 2026

Live Events

2026 SEND Explorer Virtual User Group Meeting

–

Danielle PillsburyJuly 16, 2026

Webinar

Integrated mechanistic modeling approaches in oncology drug development

CertaraJuly 8, 2026

Blog

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…

Hunter Stephens, PhDJuly 7, 2026

Blog

Enhancing clinical trials with real-world evidence in pregnancy research

Learn how real-world evidence improves clinical trials in pregnancy by enhancing safety data, trial design,…

Alekhya Lavu, PhD, PharmDJune 26, 2026

Poster

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Discover how Quantitative Systems Pharmacology (QSP) was used to predict cytokine release syndrome risk and…

CertaraJune 23, 2026

Drug Safety

Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development

Tailwinds for MIDD: EMA, FDA, and a Converging Regulatory Landscape

A glimpse into the future of model-informed drug discovery and development

The Road to First-in-Human: Model-Informed Decisions from Discovery to First Dose

Tailwinds for MIDD: What to Know About the Changing Regulatory Landscape

2026 SEND Explorer Virtual User Group Meeting

Integrated mechanistic modeling approaches in oncology drug development

Dosimetry for radiopharmaceutical therapy: From measurement to dose justification

Enhancing clinical trials with real-world evidence in pregnancy research

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Newsletter sign up

Quick links

Solutions

Contact